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Regulation of transcription from the oncogene c-myc has an important role in the genesis of various
tumors. Therefore, c-myc is a potential target for chemotherapy by drugs which are able to modify its
activity directly. In this article, we identify the binding sites in the P1 and P2 promoter regions of c-myc
for the intercalating antibiotics actinomycin D and elsamicin A. Gel retardation experiments indicate that
actinomycin D or elsamicin A binding can inhibit the formation of several DNA-protein complexes.
However, relatively low concentrations of elsamicin A, but not actinomycin D, appear to increase the
level of binding to the P1 promoter of a protein factor. Using pure Sp1 transcription factor and an
oligonucleotide containing the Sp1 putative binding site, we determined that the binding enhancement
induced by small amounts of elsamicin was on the Sp1-DNA complex. Run-off transcription experiments
in vitro showed that the effect of elsamicin A on Sp1 binding is followed by the maintenance or a relative
rise in transcription levels from the P1 promoter of c-myc, while actinomycin D always inhibited the
transcription from the P1 c-myc promoter in a concentration-dependent manner. Higher concentrations of
elsamicin acted as an inhibitor of the transcription from the P1 start site but not from the P2.
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The control of c-myc expression appears to be essential for therapeutic action through their interaction with the c-myc onco-
gene [17219]. In order to identify the mechanism by whichnormal cellular proliferation, and its failure may lead to the gen-
esis of various tumours [125]. Transcription of the c-myc gene some drugs inhibit the expression of the c-myc gene, we ana-
lyzed the binding of actinomycin D and elsamicin A within theis initiated from two major start sites termed P1 and P2, which
are located 161 bp apart in the human gene [1, 2]. In normal region 2101 to 1212 of the human c-myc promoter region. We
found that the presence of intercalating drugs can modulate theand resting cells P2 is the pivotal promoter producing up to 90%
of the c-myc mRNA, while P1 provides up to 25% of c-myc binding of several protein factors to the P1 and P2 promoter
regions, especially the Sp1 trans-acting factor, which also recog-transcripts in normal cells, but may predominate in malignant
cells [123]. Regulation has been shown to occur at multiple nizes a consensus G1C-rich tract in DNA [20]. We have also
identified the binding sites for these drugs in the promoters, andlevels and several positive and negative cis-acting elements
within a 2.3-kb region upstream of the promoters coordinate the show that certain discrete DNA-protein complexes behave dif-
ferentially in the presence of either actinomycin D or elsamicinc-myc expression in response to various physiological stimuli [1,
A since some complexes are blocked by the presence of either6, 7]. P1 and P2 appear to be regulated by a combination of
drug, while others seem to be insensitive, or even somewhatpositive and negative trans-acting factors binding within this re-
enhanced by the drugs. In general, impedence of the formationgion.
of DNA-protein complexes by the intercalating drugs producesThe antitumor antibiotics actinomycin D (dactinomycin) and
the inhibition of c-myc promoter transcription in vitro, thoughelsamicin A (elsamitrucin) [8, 9] are two DNA-binding drugs
P1 and P2 are differentially sensitive to the presence of drugwhich intercalate preferentially into G1C-rich steps [10214],
concentrations.and they are able to inhibit the transcription in vitro from pro-
karyotic and phage genes [15, 16]. However, there is an increas-
ing need to complement these studies with additional informa- MATERIALS AND METHODS
tion on the effect of other antitumor drugs on specific genes,
Protein extracts and drugs solutions. HeLa cell nuclearand in particular on c-myc, which plays a crucial role in malig-
extracts were purchased from Promega; the protein concentra-
nant cell differentiation.
tion was between 3.628.3 ìg/ml depending on the lot used. PureWe have sought to verify the notion that some drugs that Sp1 transcription factor was obtained from Promega. Actinomy-bind specifically to G1C-rich DNA might achieve their chemo-
cin D (Serva) and elsamicin A (a gift of Dr A. M. Casazza,
Bristol-Myers Squibb) were freshly prepared as 250 ìM stock
Correspondence to J. Portugal, Departamento de Biologı´a Molecular solutions in 10 mM Tris/HCl, pH 7.4, 20 mM KCl (containingy Celular, Centro de Investigacio´n y Desarrollo, CSIC, J. Girona-Sal- 25% methanol for elsamicin), and diluted to the desired concen-gado, 18226, Barcelona, Spain
trations using the same buffer without methanol prior to the ex-Fax: 134 3 204 59 04.
periments.E-mail: jpmbmc@cid.csic.es
Labeling and isolation of DNA fragments. The pGEM-Enzymes. DNase I (EC 3.1.21.1) ; Klenow enzyme (DNApolymerase
I, large fragment) (EC 2.7.7.7); T4 polynucleotide kinase (EC 2.7.1.78). myc1 plasmid, which contains the SmaI2SstI fragment of the
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human c-myc [18], was kindly provided by Dr R. Ray (Univer-
sity of St Louis). Two restriction fragments from this plasmid
were purified, SmaI2XhoI to create pVP1 and XhoI2NaeI to
create pVP2, and inserted between the SmaI2SalI sites of
pBluescribe (Stratagene), grown in Escherichia coli TG1 and
purified using CsCl and standard protocols. Hence, the pVP1
plasmid contains, in its SmaI2XhoI fragment, the c-myc region
from 2110 to 168, including the P1 initiation site (fragment
SX, see Fig. 1); while pVP2 contains, in its XhoI2NaeI frag-
ment, the c-myc region from 168 to 1212 including the P2
initiation site (fragment XN, see Fig. 1). DNA fragments (SX
and XN) to be used in the gel retardation (band-shift) and foot-
printing assays were prepared by digestion with EcoRI and Hin-
dIII followed by labeling at their 3′-ends using [A-32P]dATP and
the Klenow enzyme. The fragments were further separated from
the remainder of the plasmids by running on a non-denaturing
6% polyacrylamide gel.
A oligonucleotide containing the consensus Sp1 binding site
[20], whose sequence (upper strand) is: 5′ATTCGATCGGGGC-
GGGGCGAGC3′ (purchased from Promega) was also employed
to analyze the effect of the intercalating drugs on Sp1 binding.
It was labelled at its 5′ ends using [ª-32P]ATP and T4 poly- Fig.1. Schematic representation of the human c-myc P1 and P2 pro-
nucleotide kinase. moters. The putative Sp1 binding site, as well as the P1 and P2 start
Gel retardation assays. The gel retardation (band shift) sites, are indicated (top). The indicated restriction enzymes were used
assays were performed as described elsewhere [18] with a minor to generate the two fragments : SX (SmaI2XhoI) and XN (XhoI2NaeI).
The lower part displays the nucleotide sequences of the upper strand ofmodification: the binding buffer contained 2% glycerol and
these restriction fragments.0.02% Nonidet P-40 (Sigma). In reactions containing actinomy-
cin or elsamicin, the DNA fragments were incubated with dif-
ferent concentrations (see legends to figures) of the drugs before
0.2 mM EDTA, 2% poly(ethyleneglycol)8000 (Sigma), 300 ìMthe addition of the different amounts of protein extract, except
each of ATP, CTP and GTP, 1 ìM UTP and 20 ìCi [A-32P]UTP,where otherwise noted. A typical reaction contained 4212 ìg
in the presence of the amounts of actinomycin D or elsamicin AHeLa extract or 25 ng pure Sp1 protein and 150023000 cpm
indicated in the legend to Fig. 8. Transcription was allowed to(about 1.5 nmol in bp) of end-labelled DNA or oligonucleotide,
proceed for 60 min at 30°C and the samples were phenol-ex-in the presence of 123 ìg poly[d(I-C)] (Boehringer Mannheim).
tracted before gel loading. Transcription using HeLa wholeThe samples were analyzed on 4.5% non-denaturing polyacryl-
nuclear extracts, in either the presence or absence of additionalamide gels containing 45 mM Tris/borate, 1 mM EDTA pH 8.3.
Sp1 transcription factor (25 ng pure protein), renders two tran-After running at low voltage (12 V/cm), the gels were soaked in
scripts of 348 nucleotides (P1 promoter) and 187 nucleotidesdistilled water, dried under vacuum and subjected to autoradiog-
(P2 promoter). In the transcription experiments an internal stan-raphy. Quantitative analysis of the complex formation was per-
dard for recovery and gel loading was used (a 230-nucleotideformed with a Molecular Dynamics computing densitometer
RNA kindly provided by Dr J. Bernue´s). Transcripts were ana-using the ImageQuant 3.2 software. Each gel track, from four
lyzed by high-voltage electrophoresis in 90 mM Tris/borate,independent experiments, was normalized with respect to the
2 mM EDTA pH 8.3 using 8 % polyacrylamide gels containingtotal amount of loaded radioactivity and represented as the mean
7 M urea. After running, the gels were soaked in distilled water,value 6SD.
dried under vacuum and the bands were observed by autoradiog-DNase I footprinting. Samples containing incubated com-
raphy. The relative amounts of transcripts from both promoters,plexes of the end-labelled SX or XN fragments of the human c-
in the presence or absence of drugs, was quantified using a Mo-myc (3000 cpm, around 10 pmol in bp) and different concentra-
lecular Dynamics computing densitometer.tions of actinomycin, or elsamicin, both in the presence and the
absence of pure Sp1 transcription factor, at the concentrations
stated in the legend of Fig. 7, were digested with DNase I (Boeh-
RESULTSringer Mannheim) at a final concentration of 0.01 U/ml for
2 min at 25°C, and the reaction stopped by adding a solution The influence of actinomycin D and elsamicin A on the
containing 85% formamide 10 mM EDTA and 0.02% bromo- binding of protein factors, from nuclear HeLa extracts, to the
phenol blue. Samples were heated at 95°C for 2 min prior to human (2110 to 1 212) c-myc promoter region was examined
electrophoresis. The footprints were resolved by high-voltage using the gel retardation technique on two restrictions fragments
electrophoresis in 90 mM Tris/borate, 2 mM EDTA pH 8.3 using (designated SX and XN, see Fig. 1), which contain the P1 and
6% or 8% polyacrylamide gels containing 8 M urea, together P2 promoters respectively together with the surrounding regions.
with a dimethylsulphate-piperidine marker specific for guanine. These two DNA fragments were used to identify specific protein
After running, the gels were soaked in distilled water, dried un- complexes as well as their sensitivity to the intercalating ligands
der vacuum and the bands were observed by autoradiography. actinomycin D and elsamicin A.
In vitro transcription. The effect of actinomycin and elsam-
icin on the transcription of the human c-myc P1 and P2 promot- Actinomycin D and elsamicin A bind differentially to the P2
promoter of c-myc, and compete with protein factors forers was measured using SmaI-linearized pGEMmyc1 plasmid
digested with FokI. Run-off transcription assays in vitro were their binding sites. Fig. 2 shows a gel retardation experiment
using the XN restriction fragment of c-myc, whose sequence isperformed in a final volume of 25 ìl and contained 30 mM
Hepes pH 7.9, 7 mM MgCl2, 5 ìM ZnSO4, 1 mM dithiothreitol, displayed in Fig. 1. Four different complexes were observed
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Fig. 2. Effect of actinomycin D and elsamicin A on the binding of a
HeLa nuclear extract to the P2 promoter of c-myc. The experiments
were performed using the XN restriction fragment, whose nucleotide
sequence is displayed in Fig. 1. Lane 1, control DNA (1.5 nmol in bp);
lanes 225, gel retardation analysis of the protein binding in the presence
of increasing amounts of actinomycin D (ACTD; 1, 5, 10 and 20 ìM);
lanes 629, analysis of the protein binding in the presence of increasing
amounts of elsamicin A (ELSA; 5, 15, 50 and 150 ìM); lane 10, 8 ìg
HeLa nuclear extract plus DNA.
when this restriction fragment was incubated with HeLa extract
(designated B12B4). All of them were differentially sensitive
to actinomycin and elsamicin. The presence of the B1 protein-
DNA complex, the slowly migrating one in Fig. 2, was clearly
inhibited by the presence of either antibiotic, though the exact
concentration of drug required to inhibit the formation of the Fig.3. Analysis of the effect of actinomycin D and elsamicin A on
complex completely was higher in the case of elsamicin (com- the binding of a HeLa nuclear extract to the P1 promoter of c-myc.
pare lanes 5 and 9 in Fig. 2). Nevertheless, B2 and B3 were (A) Effect of actinomycin D and elsamicin A on the binding of a HeLa
nuclear extract to the P1 promoter of c-myc (SX restriction fragment,quite insensitive to the presence of either drug. In fact, concen-
whose nucleotide sequence is displayed in Fig. 1). Lane 1, control oftrations of elsamicin above 100 ìM were required to inhibit the
DNA (1.5 pmol in bp); lanes 2 and 8, DNA plus drugs; lanes 3 and 9,formation of such a complex. The most rapidly migrating com-
DNA plus HeLa extract ; lanes 427, analysis of the protein binding (8 ìgplex (B4) was very sensitive to actinomycin while elsamicin was
of HeLa extract) in the presence of four concentrations of actinomycin
required at concentrations about 100 ìM to prevent the forma- D (5, 15, 45 and 90 ìM); lanes 10213, analysis of the protein binding
tion of this DNA-protein complex completely (compare lanes 3 in the presence of four concentrations of elsamicin A (5, 15, 45 and
and 7 in Fig. 2). A similar result, with differential modulation 90 ìM). (B) Quantitative analysis of the effect of actinomycin D and
of DNA-protein complexes in the human c-myc P2 promoter, elsamicin A on the binding of some transcription factors to the P1 pro-
has been reported previously using mithramycin [18], a minor- moter (displayed in A), measured as the percentage of complex forma-
tion in the presence of the drugs. (n) A4 complex plus elsamicin A;groove-binding drug [21]. Several nuclear protein binding sites
(h) A4 complex plus actinomycin D; (s) A5 complex plus actinomycinhave been identified within the c-myc promoters [1, 2, 22]. Al-
D. The data represent the mean of four independent experiments likethough our band-shift results are consistent with the presence of
those in A (mean value 6SD).such binding sites, the detection of a different number of pro-
tein2DNA interactions might originate from the different pro-
tein composition or stability of the HeLa nuclear extracts, since
two different preparations containing the same amount of pro- elsamicin and actinomycin in a concentration-dependent manner.
teins do not necessarily contain the same number of active pro- All the complexes were observed in the protein-DNA control
tein factors. In any case, the behavior of the different complexes experiment (lanes 3 and 9) whereas they were not observed in
in the presence of elsamicin and actinomycin was consistent the control of DNA alone (lane 1). The rapidly migrating pro-
with the binding of these drugs to G1C-rich regions [10, 11] as tein-DNA complex, named A5, was clearly dissociated by acti-
it is in the experiments with mithramicin [18]. Notwithstanding, nomycin D at concentrations above 15 ìM, while it remained
there were differences in the concentration dependence of the quite insensitive to elsamicin up to the same concentration. The
inhibition by the three drugs which may have arisen from a more presence of actinomycin produced a diminution in the intensity
pronounced effect of the intercalators on DNA structure, or the of the A2 and A4 complexes in a concentration-dependent man-
respective binding constants of the intercalating ligands. ner. The incubation of the labelled DNA with the protein extract
and either actinomycin D or elsamicin A added simultaneously
also resulted in the inhibition of most of the DNA-protein com-At some concentrations elsamicin A might relatively enhance
the binding of Sp1 protein factor to the P1 promoter of c- plexes (results not shown). Elsamicin A produced a relative
increase of the A4 band at concentrations between 5215 ìMmyc. A band shift analysis of the SX fragment, which contains
the P1 start site, is displayed in Fig. 3A. At least six different (lanes 10 and 11), although the shifted band of the complex was
always less intense than in the absence of the drug (compareprotein-DNA complexes were detected when this restriction
fragment was used under the experimental conditions described lanes 8 and 11 in Fig. 3 A). At higher amounts of elsamicin a
concentration-dependent disassociation of the DNA-proteinin Materials and Methods. They were differentially sensitive to
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Fig.5. Effect of actinomycin D and elsamicin A on Sp1 binding to
an end-labelled oligonucleotide containing its consensus binding se-
quence. Lanes 124, control lanes for DNA, protein, and drug com-
plexes; lanes 527, Sp1 binding in the presence of increasing amounts
of actinomycin D (ACTD; 2, 6, 15 ìM); lanes 8210, Sp1 binding in
the presence of increasing amounts of elsamicin A (ELSA; 2, 6, 15 ìM).
Fig. 4. Displacement of the complex A4 by increasing amounts of the cules (upper band in Fig. 4, lane 2). It seems that when Sp1 is
oligonucleotide 5′ATTCGATCGGGGCGGGGCGAGC3′ containing displaced by the specific oligonucleotide, there is also a diminu-
the Sp1 consensus sequence. The end-labelled SX fragment of c-myc tion in the intensity of the slowly migrating band, although it is
was incubated with increasing amounts of unlabelled oligonucleotide, in
not completely removed at the concentrations used to displacethe presence of 8 ìg HeLa extract. Lane 1, DNA fragments ; lane 2,
the A4 band. We verified our interpretation that the two bandsDNA plus 25 ng pure Sp1 ; lane 3, DNA plus HeLa extract ; lanes 426,
observed should correspond to Sp1 binding as a monomer or0.15, 0.28 and 0.84 ng oligonucleotide, respectively. The band displaced
homodimer complex, respectively, by the presence of a uniqueby competitive binding is indicated with an arrow.
electrophoretic band in experiments performed with a labelled
oligonucleotide containing a unique Sp1 binding site (Fig. 5).
To seek new insight into the effect of actinomycin D andcomplex occurred as for actinomycin. The behavior of the A4
protein-DNA complex was reasonably reproducible in four inde- elsamicin A on the binding of Sp1 to its recognition site, we
performed band-shift experiments with pure Sp1 protein on bothpendent experiments. The plot in Fig. 3 B shows a quantitative
analysis of the complex formation in these experiments. The the oligonucleotide (5′-ATTCGATCGGGGCGGGGCGAGC-3′,
as a double strand) and the SX fragment that contains the puta-interference of elsamicin and actinomycin on the formation of
the A4 complex was determined from densitometric scans (see tive Sp1 binding site [20] in the c-myc promoter. Illustrated in
Fig. 5 are the effects of different drug concentrations on theMaterials and Methods). The dose/response curves in Fig. 3 B
compare drug-treated samples with those obtained in the absence binding of Sp1 to the oligonucleotide containing its consensus
sequence. The retarded electrophoretic band, which correspondsof any drug. They substantiate, within experimental error, the
enhancement of the A4 band due to the binding of elsamicin, to the analyzed DNA-protein complex (lane 2 in Fig. 5), was
sensitive to both actinomycin and elsamicin in a concentration-after a previous decay. A further probe of this enhancement was
obtained using pure protein (see below). dependent manner as detected by a titration of the previously
formed protein-DNA complex using increasing amounts of acti-To evaluate the effectiveness of both drugs as inhibitors of
DNA-protein complex formation, we established conditions of nomycin D (lanes 527) or elsamicin A (lanes 8210). 6 ìM acti-
nomycin produced more than 90% inhibition of the DNA com-the assay to maximize complex formation. The temperature for
incubation and electrophoresis were optimized to enhance the plex, while at the same concentration, or even at smaller ones,
elsamicin completely prevented the formation of an Sp1-oligostability of the DNA-protein complexes (see Materials and
Methods). Due to the peculiar behavior of complex A4, we at- complex. These results agree with a competition between the
two drugs, which are G1C sequence-selective binding ligandstempted to identify the relationship between this particular band
and some putative protein factors that have been described to [10, 23], and the purified Sp1 protein factor binding to the pro-
moter regulatory element containing a G1C-rich tract.bind to this region of c-myc [2]. Fig. 4 shows a competition
experiment between increased amounts of an unlabelled oligo- At first sight, the results obtained with elsamicin A (Fig. 5),
seem to be at variance with a the relative increase of the com-nucleotide, which contains the consensus sequence for Sp1 bind-
ing [20], and the SX end-labelled fragment. One of the radio- plex that was observed when total HeLa extract and the SX re-
striction fragment described above were employed (Fig. 3). Inactive bands, which appears to be the same as complex A4 (cf.
Figs 3A and 4), clearly decreased in the presence of the unla- order to investigate the modulation of Sp1 binding to the c-myc
promoter by elsamicin A, and to gain further information on thebelled competing oligonucleotide while the intensity of the other
bands remained practically unaltered. This led us to identify the effect of some antitumor antibiotics on the promoter region of
c-myc, we also performed experiments with purified human Sp1band, the intensity of which was modulated in direct proportion
to the amount of elsamicin added, as produced by Sp1 binding transcription factor and the SX fragment. In Fig. 6 the Sp1-DNA
electrophoretic band was sensitive to actinomycin D with con-(lanes 10213 in Fig. 3A). A putative Sp1 binding site is located
upstream the P1 promoter of c-myc (see Fig. 1). It consists of centrations of around 5 ìM preventing the formation of DNA-
protein complexes. However, while Sp1-DNA complex forma-two overlapping Sp1 binding sites, which can bind either a
single Sp1 (giving the electrophoretic band that runs ahead) or tion seemed to be fairly blocked around 1.5 ìM elsamicin A
(Fig. 6 B, lane 6), at higher concentrations (lanes 729) thea slowly migrating band due to the binding of two Sp1 mole-
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Fig. 6. Analysis of the effect of actinomycin D on Sp1 binding to the P1 promoter. (A) Effect of actinomycin D on Sp1 binding to the P1
promoter (SX restriction fragment whose nucleotide sequence is displayed in Fig. 1). Lane 1, DNA alone ; lane 2, DNA plus 25 ng pure Sp1 ; lane
3, DNA plus 15 ìM actinomycin D (ACTD), lane 4, DNA plus 15 ìM elsamicin A (ELSA); lanes 529, DNA-Sp1 complex incubated with
increasing concentrations of actinomycin D (0.1, 0.5, 1, 5 and 15 ìM). (B) Effect of elsamicin A on Sp1 binding to the same fragment containing
the P1 promoter. Lane 1, DNA alone ; lane 2, DNA plus 5 ìM elsamicin A; lane 3, DNA plus 25 ng pure Sp1 ; lanes 4210, DNA-Sp1 complex
incubated with increasing concentrations of elsamicin A (0.5, 1, 1.5, 2, 2.5, 5 and 15 ìM).
electrophoretic band increased slightly, in agreement with the
observations using total nuclear HeLa extract described above
(compare Figs 3 and 6B). There is also a clear effect on the
slowly migrating band, which would correspond to the binding
of two Sp1 molecules as described above. When higher concen-
trations (around 15 ìM) were used there was an inhibition of
the complex formation. These experiments were also performed
using different concentrations of elsamicin and the results were
unambiguously reproducible. In any case, the DNA concentra-
tion in the band shifts was about 1.5 nmol (in bp), so that there
was a molar excess of both purified Sp1 and drug molecules.
As a result, under our experimental conditions, the amount of
drug that can block (or enhance) the binding of the transcription
factor to DNA (or compete for the G1C-rich zones in DNA)
was limited by the equilibrium binding constant of the reaction
rather than by the drug/DNA stoichiometric ratio.
Footprinting analysis showed that Sp1 and elsamicin A can
compete for their overlapping binding sites. DNase I foot-
printing experiments were performed to characterize binding of
the pure Sp1 protein to the P1 promoter of c-myc, in the pres-
ence and absence of actinomycin and elsamicin. By using this
approach, it is feasible to assess the overlapping binding sites of
Sp1 and either actinomycin or elsamicin A to the c-myc P1 pro-
moter. In all respects, binding of these drugs to the SX restric-
tion fragment, in the absence of the protein factor, produced a
footprinting pattern (Fig. 7) which resembled those obtained for
these antibiotics on other DNA fragments [10, 11]. The reactions
containing Sp1 showed a clear protection in a wide region of
the P1 promoter. The presence of 5 ìM actinomycin D or elsam-
icin A produced a clear footprint in the region which overlapped
the Sp1 footprint. We consider that either actinomycin or elsami-
Fig.7. DNase I footprinting of Sp1 and actinomycin D or elsamicincin can compete with the protein binding to its putative site in
A binding to the P1 promoter region. Lane 1, dimethylsulphate-piperi-the c-myc P1 promoter in a concentration-dependent way. The dine markers specific for guanine; lane 2, DNase I cleavage in the pres-
experimental fact that elsamicin and actinomycin bind exten-
ence of 5 ìM elsamicin A (ELSA) plus 50 ng pure human Sp1 ; lane 3,
sively to the same sites as Sp1 suggests that spacious overlap- in the presence of 5 ìM elsamicin A; lane 4, in the presence of 150 ng
ping of the binding sites is required to inhibit the binding of the pure Sp1 ; lane 5, labelled DNA alone (control); lane 6, 5 ìM actinomy-
protein factor, in agreement with the footprinting pattern gener- cin D (ACTD); lane 7, 5 ìM actinomycin D plus 50 ng Sp1. The region
corresponding to the Sp1 footprint is indicated on the figure.ated by mithramycin binding to the Sp1 binding site [18]. In the
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Fig.9. Quantitative analysis of the effect of elsamicin A (ELSA) or
actinomycin D (ACTD) on transcription from the c-myc promoter.
(h) P1 promoter; (j) P2 promoter. The bars correspond to the relative
amount of transcript obtained in comparison to the basal transcription
(lane 2 in Fig. 8), and considering 100% for the c-myc transcription fromFig. 8. Effect of actinomycin D and elsamicin A on in vitro run-off
P1. Sp1 produces a clear activation of its proximal promoter (P1, seetranscription from the c-myc P1 and P2 promoters by HeLa extract.
Fig. 1) but not P2. The densitometric profiles used to generate the plotLane 1, a size marker (end-labelled HinfI digest of fX174 DNA) used
were corrected for any gel loading artifact using the band (marker) indi-to locate the transcripts; lane 2, transcripts from the c-myc P1 and P2
cated by an asterisk in Fig. 8. The transcripts obtained in the presencepromoters (control); lane 3, transcripts obtained using whole HeLa ex-
of 1 ìM actinomycin D (lane 5 in Fig. 8) were not considered in thistract plus added pure Sp1 (25 ng); lanes 426, effect of increasing
quantitative analysis since the sample was deemed to be unevenly load-amounts of actinomycin D (ACTD; 0.5, 1, 5 ìM) on the run-off tran-
ed.scription; lanes 729, effect of increasing amounts of elsamicin A
(ELSA; 0.5, 1, 5 ìM) on the run-off transcription. Note that in these
transcription experiments an internal standard for recovery and gel load-
ing was used (indicated by an asterisk).
ing site in the c-myc promoter (see Fig. 1). Actinomycin D
strongly inhibited the transcription from P1 at all the concentra-
footprinting studies, we did not find any symptom of increased tions tested (Fig. 8, lanes 426) while transcription from the P2
binding of Sp1 by added elsamicin, as described in the band- remains almost unaltered (lane 5 in Fig. 8 should not be taken
shift studies (Figs 326) or the transcription assays in vitro, de- in consideration at this point since it seems to show an unevenly
scribed below; undigested material is obviously difficult to ob- loaded sample). In the presence of 0.5 ìM elsamicin, the tran-
serve in a region that is already protected from DNase I cleav- scription was active from both the P1 and the P2 start sites (lane
age, though the phenomenon might exist. In Fig. 7, the differ- 7). From P1 it even appeared to be fairly enhanced at concentra-
ences between the DNase I cleavage enhancements in lanes 2 tions around 1 ìM. Higher concentrations of elsamicin were re-(elsamicin 1 Sp1) and 7 (actinomycin 1 Sp1) support this inter- quired to completely inhibit transcription from P1. Fig. 9 shows
pretation. An undigested region at the 3′ site of the c-myc P1 a quantitative analysis of the transcription from P1 and P2 pro-promoter (upper part of the gel) is observed in the presence of
moters in which the amount of transcription has been normalized
elsamicin A, or mithramycin [18], but not actinomycin D. It may
using a standard for recovery and loading (indicated with an
correspond, at least in part, to a distortion of the DNA structure
asterisk in Fig. 8). The P2 transcript was clearly enhanced in the
after Sp1 binding, since Sp1 binding can induce significant presence of 5 ìM elsamicin while transcription from P1 was
structural distortions at the 3′ site of G1C-rich regions [24]. It
strongly inhibited (Figs 8 and 9). These results are consistentis worth mentioning that this region contains the TATA box of
with the general inhibition, by actinomycin D, of c-myc tran-P1 (see Fig. 1), which does not coincide with a preferred binding
scription from the P1 promoter in a concentration-dependentsite for the drugs studied here.
manner. They also agree with the relative increment of Sp1 bind-
ing in the presence of some concentrations of elsamicin A, de-Elsamicin A changes the affinity of Sp1 protein for the P1
scribed in the band-shift assays and the correct assembly of thepromoter while it can either inhibit or enhance the tran- initiation complex on the P1 promoter at low concentrations ofscription from P2 c-myc promoter. To detect the effect of acti-
elsamicin (1 ìM). These might result in the maintenance of tran-nomycin D and elsamicin A on the transcription activity from
scription levels and a slight increase in the yield of total tran-the P1 and P2 promoters of c-myc in vitro, we undertook a run-
script formed from the P1 start site (see the quantitative analysisoff transcription assay using the pGEMmyc1 plasmid (see Mate-
in Fig. 9) but not from the P2 start site, which is further fromrials and Methods). P1 and P2 transcripts (348 and 187 nucleo-
the Sp1 binding site than the P1 promoter [2]. Surprisingly, oncetides) are clearly visible in the control (no drug added, Fig. 8,
P1 is inhibited (Fig. 8, lane 9) there is a manifest increase inlanes 2 and 3). Lane 3 shows the result of the trancription using
transcript yield from the P2 promoter. Tentatively, we suggestHeLa extract plus added Sp1 protein (25 ng) to check the effect
that this situation arises from a redistribution of some basalof elsamicin A and actinomycin D on its binding through the
trans-acting factors due to the stronger binding of the drug in aindirect effect on transcription of the c-myc promoter by whole
region close to P1. Some effects of drugs in the relative forma-HeLa extract. Lane 3 shows that adding pure Sp1 to a HeLa
tion of multimeric protein complexes have been described, as forextract (which already contains Sp1) produced an enhancement
example some intercalators that affect the interaction between aof the amount of transcript from P1 but not from P2 promoter,
as would be expected from the relative location of the Sp1 bind- growth response factor and the TATA-box binding protein [25].
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DISCUSSION teristics of the c-myc P1 promoter or elsamicin A. However,
since we added some pure Sp1 in the run-off experiments, it was
While, in general, the major groove of DNA is recognized unambiguously established that the changes in the yield of RNA
by many, but not all, trans-acting protein factors, the minor from P1 were intimately related to the levels of Sp1 binding to
groove is employed by several drugs, including many intercalat- the P1 promoter region (see the quantitative analysis in Fig. 9).
ing agents which are known to exert antitumor activity. The ex- At the same time, there was a general inhibition of the transcrip-
perimental approaches presented in this article indicate that two tion due to the binding of the drugs to other C1G-rich regions.
such intercalators, actinomycin D and elsamicin A, might induce Several lines of evidence also show that elsamicin and actino-
a specific release of some proteins which selectively bind to the mycin might behave differentially in transcription from phage
human c-myc promoter. Hence, it is feasible to inhibit the bind- genes while still acting as transcription inhibitors [16]. The ef-
ing of regulatory proteins to DNA using small ligands [26, 27]. fects of actinomycin and elsamicin are not due to their direct
This effect may be responsible for the differential modulation of interaction with the Sp1 protein alone, as indicated by incubating
the transcription of a particular gene by intercalating agents drug and protein together first (details not reported).
(c-myc should be considered an example). In the run-off transcription experiments using human c-myc
By exploring the band-shift assays (Figs 2 to 6) and the (Fig. 8), a slight increment of transcripts from P1 at 1 ìM elsam-
DNase I footprinting (Fig. 7), we can observe several DNA-pro- icin is evident (after inhibition at lower concentrations), in
tein complexes that can be completely inhibited or/and dissoci- agreement with the effect mediated through Sp1 recognition of
ated. The results presented in this article accord with the view its consensus sequence observed in the band-shift assays. Never-
that low-molecular-mass ligands are able to displace proteins theless, the drug somewhat retains the transcription to a level
bound to DNA [25228]. A possible explanation is that the com- similar to that the transcription obtained using HeLa extract
petition observed is caused by a change in the local DNA con- alone, but without reaching the amounts for the HeLa1Sp1
formation. This may be mediated by the unwinding of the poly- (lanes 2 and 3 in Fig. 8). It is likely that the binding of elsamicin
nucleotide induced by the intercalation. Nevertheless, it is worth to other C1G-rich sites in the promoter acts as an inhibitor of
noting that minor-groove binding ligands, which are considered transcription, as observed with actinomycin (Fig. 8, lanes 426).
to distort DNA to a lesser extent, can also inhibit the formation Hence, the effect on Sp1 binding is partially masked, yet it is
of DNA-protein complexes [22, 28]. quantitatively evident in Fig. 9. The abilities of small ligands to
Experiments using pure Sp1, and either the P1 promoter or both augment and arrest transcription by RNA polymerase II in
a consensus oligonucleotide, indicate that actinomycin D and a concentration-dependent fashion does not seem to be a pecu-
elsamicin A overlap the Sp1 binding site, thus preventing protein liarity of the drugs and/or promoters used in this article, since
binding (at any actinomycin concentration and relatively high the ability of some intercalating drugs as well as minor groove
concentrations of elsamicin). Under certain concentration-de- binders to enhance and/or impede RNA elongation has been de-
pendent conditions, the protein binding to the preferred sequence scribed elsewhere [19, 28, 29]. Notwithstanding, with elsamicin
is maintained and sometimes it appears to be relatively enhanced the inhibition of the transcription from P1 was concomitant with
in the vicinity of the P1 promoter. This enhancement is not ob- the increase in transcript yield from P2, which might be ex-
served when Sp1 is bound to a synthetic oligonucleotide that plained by considering that the some protein factors released
lacks the flanking sequences in the c-myc promoter. Since from the P1 promoter bind to the P2 promoter, thus activating
DNase I footprinting establishes that both drugs bind preferen- the initiation from the P2 start site (Fig. 8, lane 9, and Fig. 9).
tially to C1G-rich regions in DNA [10, 11] including the c-myc Nevertheless, our results point out the occurrence of this dual
promoters (see Fig. 7), the relative enhancement in the Sp1- effect in the transcription of an oncogene in the presence of
DNA complex in Figs 3 and 6 (in the presence of some concen- clinically useful drugs under physiologically relevant concentra-
trations of elsamicin, but not in the presence of any concentra- tions.
tion of actinomycin) deserves further discussion. We tentatively So far as our results go, it seems likely that the concentra-
consider that elsamicin A intercalates at DNA regions located tion-dependent response of c-myc promoter to elsamicin A is
within or in the vicinity of the Sp1 binding site using the unoc- mediated by changes in the affinity of Sp1. The concentrations
cupied minor groove and changing DNA to a more-favored con- of elsamicin required to observe the relative enhancement of
formation for Sp1 binding, while actinomycin might occupy all protein binding (Fig. 3) or to increase the transcription yield
the C1G-rich regions and perhaps other weaker binding sites (Fig. 8) are fairly different. They possibly reflect the distinct ex-
[14], thus making some of the DNA-protein complexes more perimental conditions in the band-shift and run-off transcription
sensitive than others. The binding of elsamicin is somewhat experiments. RNA polymerase II needs to read through natural
driven by the flanking sequences since the phenomenon is not pause sites, in which the polymerase proceeds slowly [7, 30].
observed on the consensus oligonucleotide (Figs. 5 and 6). The Elsamicin might act by allowing these pauses to be overridden.
conformational change produced by elsamicin binding could This explanation is consistent with the role assigned to the levels
increase the affinity constant of the Sp1 protein for its consensus of Sp1 in eliminating the promoter proximal pausing of RNA
sequence. In the P1 promoter of c-myc there are two overlapping polymerase in c-myc [7]. A direct link between the capacity of
sequences with eight bases identical with the consensus se- elsamicin to modulate c-myc expression and to influence biolog-
quence [2, 18]. The ability of elsamicin A to form a ternary ical processes will require further experiments in vivo. The re-
complex, with Sp1 and the P1 promoter DNA, may lead to the sults described here represent a new step towards the design of
stability of the protein-DNA complex at moderate drug concen- such experiments.
trations, but not at higher ones. The run-off transcription experi-
ments (Figs 8 and 9) agree with such an interpretation. There
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